NIH, NIST researchers use artificial intelligence for quality control of stem cell-derived tissues


Technique key to scale up manufacturing of therapies from induced pluripotent stem cells. Researchers used artificial intelligence (AI) to evaluate stem cell-derived "patches" of retinal pigment epithelium (RPE) tissue for implanting into the eyes of patients with age-related macular degeneration (AMD), a leading cause of blindness. The proof-of-principle study helps pave the way for AI-based quality control of therapeutic cells and tissues. The method was developed by researchers at the National Eye Institute (NEI) and the National Institute of Standards and Technology (NIST) and is described in a report appearing online today in the Journal of Clinical Investigation. NEI is part of the National Institutes of Health.

Duplicate Docs Excel Report

None found

Similar Docs  Excel Report  more

None found